{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-053131","form_type":"8-K","ticker":"COGT","cik":"0001622229","company_name":"Cogent Biosciences, Inc.","filed_at":"2026-02-17T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.665619+00:00","generated_at":"2026-05-16T02:26:24.788757+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Cogent Biosciences reports Q4/FY2025 results; advances bezuclastinib NDAs in SM and GIST","bullets":["SUMMIT NDA for bezuclastinib in NonAdvSM submitted Dec 2025; APEX NDA for AdvSM on track for 1H 2026.","PEAK NDA for bezuclastinib in 2L GIST initiated under RTOR and BTD; completion expected April 2026.","Cash, equivalents and marketable securities $900.8M as of Dec 31, 2025, sufficient into 2028.","Net loss $102.5M in Q4 2025, $328.9M full year, vs $67.9M and $255.9M in prior year periods.","Inducement grants: options to purchase 59,300 shares and 47,000 RSUs to 12 new employees."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-053131","json":"https://secwatch.observer/filing/0001193125-26-053131.json","markdown":"https://secwatch.observer/filing/0001193125-26-053131.md","text":"https://secwatch.observer/filing/0001193125-26-053131.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1622229/000119312526053131/0001193125-26-053131-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1622229/000119312526053131/cogt-20260217.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T02:26:24.788757+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}